Drugs targeting the S1P-receptor pathways are evolving as well as apoM-modulating drugs with a focus on cardiovascular diseases and inflammation; however, only a few of these studies have also reported data that are relevant to kidney biology. Here, APOM is linked to cardiovascular disorder.